Biblio
Autophagy stimulated proliferation of porcine PSCs might be regulated by the canonical Wnt signaling pathway. Biochem Biophys Res Commun. 2016.
. Characterization of Immortalized Dairy Goat male Germline Stem Cells (mGSCs). J Cell Biochem. 2014.
Correction: TET2 deficiency promotes MDS-associated leukemogenesis. Blood Cancer J. 2023;13(1):174.
EIF2S3Y suppresses the pluripotency state and promotes the proliferation of mouse embryonic stem cells. Oncotarget. 2016.
. . . Generation of pure monocultures of human microglia-like cells from induced pluripotent stem cells. Stem Cell Res. 2020;49:102046.
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML. Aging (Albany NY). 2020;12.
Identification and Validation of NK Marker Genes in Ovarian Cancer by scRNA-seq Combined with WGCNA Algorithm. Mediators Inflamm. 2023;2023:6845701.
. Identification of New Compounds against PRRSV Infection by Directly Targeting CD163. J Virol. 2023:e0005423.
miR-375 controls porcine pancreatic stem cell fate by targeting 3-phosphoinositide-dependent protein kinase-1 (Pdk1). Cell Prolif. 2016;49(3):395-406.
. Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia. Sci Transl Med. 2023;15(689):eabq8513.
RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling. J Exp Clin Cancer Res. 2024;43(1):45.
. SerpinB1 promotes the proliferation of porcine pancreatic stem cells through the STAT3 signaling pathway. J Steroid Biochem Mol Biol. 2019:105537.
. Single-cell long-read sequencing in human cerebral organoids uncovers cell-type-specific and autism-associated exons. Cell Rep. 2023;42(11):113335.
. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody. J Immunother. 2015;38(6):217-228.
. . Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):57.
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting. Exp Hematol Oncol. 2024;13(1):17.